Board of Directors
Our greatest strength and most invaluable assets lie in our people. The members of our board are comprised of the industry's brightest and most seasoned minds, shaping our distinctive approach towards patients, consumers, and customers.
Ms. Nandini Piramal is the Chairperson at Piramal Pharma Limited. She is responsible for setting strategy and driving results at Piramal Pharma Limited. Piramal Pharma Limited offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.
Additionally, she heads the Human Resources, Finance, Risk, Information Technology and Quality functions at Piramal Pharma Limited.
Ms. Piramal is also a Non-Executive Director, Piramal Enterprises Limited, and an advisor to Piramal Foundation which has impacted the lives of over 113 million Indians in its lifetime in areas ranging from gender, public health to education and purified water.
She is a visionary business leader driven by her commitment to bettering society. Her efforts in the business and social world led to her being recognized amongst 'India's Most Powerful Women' by Business Today in 2020 and 2022 for her outstanding contribution in business and social growth. She was also awarded as a 'Young Global Leader' in 2014 by the World Economic Forum.
Ms. Piramal holds a BA (Hons.) in Politics, Philosophy, and Economics from Oxford University. She also has an MBA from Stanford Graduate School of Business.
Mr. Peter DeYoung is the CEO of Piramal Global Pharma, Piramal Pharma Limited, and a member of the Piramal Pharma Limited Board. In his current role, Mr. DeYoung is responsible for steering strategy and driving profitable growth of the businesses. He has also previously handled leadership mandates as the CEO of Piramal Critical Care and President of Piramal Life Sciences.
Prior to Piramal Pharma Limited, Mr. DeYoung worked in various investing and consulting roles in healthcare across the USA, Europe, and India. After graduation, he joined McKinsey & Company in New York, working on projects for pharmaceutical and medical device companies. He was part of the Global Health Initiative at the World Economic Forum (WEF) in Geneva, Switzerland. Post his stint with WEF, Mr. DeYoung returned to McKinsey, first in New York and later in Mumbai, where he focused on the pharmaceutical and healthcare practices. He played a role in significant transactions across a broad spectrum of industry sectors at McKinsey. After McKinsey, he joined the Blackstone Group’s Private Equity Division in Mumbai.
Mr. DeYoung holds a Bachelor of Science Degree in Engineering from Princeton University, graduating summa cum laude, before completing his Master’s in Business Administration from Stanford University, where he was an Arjay Miller Scholar.
With over 25 years of overall experience in the field of finance, Mr. Vivek Valsaraj has been associated with the Piramal Group for over 21 years. He currently oversees the Finance and Shared Services Functions in the group. Mr. Valsaraj is also an Executive Director on the board of Piramal Pharma Limited and is serving on the board of the joint venture company Allergan India Private Limited and several overseas subsidiaries.
Within the group, he has been associated with various roles in Corporate and the erstwhile Domestic Formulations business. He also serves as the CFO of the Pharma business. His expertise spans across Corporate Finance, Business Strategy, Mergers and Acquisitions, Corporate Structuring, Corporate Governance & Risks, and Taxation. Over the last several years, he has been closely associated with the Pharma business and has been a part of several key acquisitions and capital raising. He has also played a key role in streamlining and finessing systems, processes, and internal controls.
Prior to joining Piramal, he was associated with companies like Wockhardt Ltd and Bharat Bijlee Ltd. He holds a Bachelor’s degree in Commerce and is an associate member of the Institute of Cost Accountants of India.
Mr. S. Ramadorai is currently the Chairman of the Advisory Board at Tata STRIVE, which is the Tata Group’s CSR skill development initiative. He is also the Chairman of Tata Technologies Limited and additionally serves as an Independent Director on the Boards of Piramal Enterprises Limited and DSP Investment Managers. In March 2016, he retired as the Chairman of the Bombay Stock Exchange (BSE Limited) after having served on their board for a period of 6 years.
Mr. Ramadorai is the Chairman on the Council of Management at the National Institute of Advanced Studies (NIAS). He is the President of the Society for Rehabilitation of Crippled Children (SRCC) and was also appointed as the Chairperson of the Kalakshetra Foundation’s Governing Board by the Union Ministry of Culture in 2020.
Mr. S. Ramadorai was in public service from February 2011 to October 2016. During his tenure as the Chairman of the National Skill Development Agency (NSDA) and the National Skill Development Corporation (NSDC) his approach was to standardize the skilling effort, ensure quality and commonality of outcomes by leveraging technology and create an inclusive environment to co-operate, collaborate & co-exist.
He took over as the CEO of Tata Consultancy Services (TCS) in 1996, when the company’s revenues were at $ 155 million. He then steered the company into becoming a $ 6 billion global IT services company by 2009.
Mr. Ramadorai was awarded the Padma Bhushan (India’s third highest civilian honour) in January 2006. In April 2009, he was conferred the CBE (Commander of the Order of the British Empire) by Her Majesty Queen Elizabeth II. In 2016, he was also awarded The Economic Times - Lifetime Achievement Award for his glorious contribution to Tata Consultancy Services.
Mr.Ramadorai has a Bachelor’s degree in Physics from Delhi University (India), a Bachelor of Engineering degree in Electronics and Telecommunications from the Indian Institute of Science, Bengaluru (India) and a Master’s degree in Computer Science from the University of California - UCLA (USA). In 1993, Mr. Ramadorai attended the Sloan School of Management’s highly acclaimed Senior Executive Development Program.
Among his many interests, Mr. Ramadorai is also passionate about photography and Indian classical music.
Mr. Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a member of Pfizer’s Global Manufacturing Leadership Team with responsibilities for global procurement, global external supply and a portfolio of Pfizer internal manufacturing sites in North America, Europe and Asia.
Later, he served as General Manager of Pfizer’s contract manufacturing business and as Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and currently serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.
Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese including a 3-year expatriate assignment in France.
He holds a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.
Mr. Jairaj Purandare has close to four decades of experience in accounting, tax, and business advisory. He is an authority on tax and regulation. He has published papers on subjects like inbound/outbound investment structuring, international tax, transfer pricing, M&As and Indian Budget and Economy. He has advised clients across various industries such as Financial Services, Infrastructure, Power, Telecom, Media, Pharma and Auto sectors that include Citibank, GE, HSBC, Hutchison, Pepsico, Standard Chartered Bank, STAR and Tata Group.
Mr. Purandare is the Founder Chairman of JMP Advisors Pvt Ltd, a leading advisory, accounting, tax and regulatory services firm in India. His previous associations has been with firms in various roles such as Regional Managing Partner, Chairman, Tax and Country Leader, Markets & Industries of PricewaterhouseCoopers (PwC) India, Chairman of Ernst & Young India (EY) and the Country Head of the Tax & Business Advisory practice of Andersen India.
Mr. Purandare is an Independent Director on the Boards of three large companies. He is a frequent speaker at Indian and international seminars and industry forums.
He is a fellow of the Institute of Chartered Accountants of India, a steering committee member for the ITSG International Network; and a member of the City of London Advisory Council for India. He is a former member of the National Council of Confederation of Indian Industry (CII) and former Chairman of the Taxation Committee of CII. He has been a member of the Central Direct Taxes Advisory Committee, chaired by the Finance Minister. Mr. Purandare was also the Regional Networks Chair and Finance Chair of YPO Gold and continues to be a member.
He has completed the YPO Presidents Program from Harvard Business School and holds a Bachelor of Science (Hons) degree from the University of Bombay.
Ms. Vibha Paul Rishi is a Non-Executive Independent Director, Piramal Pharma Limited.
Ms. Rishi is a marketing professional, specializing in Indian and international markets. She has worked at senior positions globally in branding, strategy, innovation and human capital. She started her career with the Tata Administrative Services and was part of Titan Watches’ founding team. Ms. Rishi had a long association with PepsiCo spanning close to two decades in marketing and innovation roles for India, USA and the UK. She was also the Executive Director (Brand and Human Capital) at Max India Ltd. and the Director (Marketing and Customer Strategy) at the Future Group with stints across the globe, coupled with an abiding passion for people.
Ms. Rishi currently serves on the board of several reputed companies including Tata Chemicals Limited, ICICI Bank Limited, ICICI Prudential Life Insurance Company Limited, Asian Paints Limited and others. She is also on the Board of Pratham, an NGO that works to provide education to underprivileged children in India.
Ms. Rishi holds a BA Degree in Economics from Lady Sri Ram College, University of Delhi and an MBA with specialization in marketing from the Faculty of Management Studies, New Delhi.
Mr. Sridhar Gorthi is the founding partner and member of the Management Committee at Trilegal. He is an authority in corporate law, M&A, and private equity, spanning across sectors including manufacturing, pharmaceuticals, insurance, banking and financial services, technology, telecom and media.
Among his notable achievements, Mr. Gorthi played a role in Heineken acquiring a controlling stake in United Breweries, supported Goldman Sachs in its investment in Aragen Life Sciences, and advised Intel and Qualcomm on their investments in Jio Platforms.
His domain knowledge has earned him the recognition of a ‘Leading Individual - Corporate/M&A’ by the Asia-Pacific Legal 500 and a ‘Distinguished practitioner’ for M&A and PE by the Asia law Profiles. His name also lists as a ‘Highly Regarded’ lawyer by the IFLR1000 Asia Pacific 2021, an independent firm that evaluates law firms and practitioners based on their work. He is one of India’s top 100 lawyers and part of the ‘A-list’ of the India Business Law Journal 2020,and among Chambers and Partners’ Asia Pacific’s leading lawyers in India for Banking and Finance (2014-2021).
Mr. Gorthi is a graduate from National Law School, Bengaluru, and is a member of the Bar Council of Maharashtra and Goa.
Ms. Nathalie Leitch has over 20 years of experience in the pharmaceuticals industry across multiple segments. She has led commercial management of a branded product line and oversaw the largest pipeline of generic products in the industry. A subject-matter expert in the US generics industry, Ms. Leitch has domain experience in creative product strategies and 505(b)(2) formulations; patent challenges, Hatch-Waxman and settlement options; business development and external-partnering activities. Additionally, she has extensive knowledge of sales, marketing, R&D and manufacturing functions.
Ms. Leitch has steered organizational success in the generic retail and institutional markets. She held senior leadership positions at Fresenius Kabi, Teva Pharmaceuticals, Allergan plc, and Actavis (formerly Watson). She has been instrumental in driving company acquisitions and overall consolidation.
Ms. Leitch has a B.Sc. in Human Biology from Trinity College, University of Toronto, Canada, and holds a Finance MBA from Queen’s University, Kingston, Canada.
Mr. Neeraj Bharadwaj is the Managing Director of Carlyle India Advisors Private Limited, focused on growth capital and buyout opportunities across sectors in India. Prior to joining Carlyle in 2012, Mr. Bharadwaj was a Managing Director with Accel Partners’ growth investing operation in India.
Preceding that he was with Apax Partners for nearly 10 years - he was a Partner in the U.S. and subsequently Managing Director/Country Head for Apax in India, where he led the India operations. Investments he has been involved with include Apollo Hospitals (BSE: AHEL), Jamdat (NASDAQ: JMDT), Widerthan (NASDAQ: WTHN) and others. Previously, Mr. Bharadwaj was an engagement manager at McKinsey & Co. Mr. Bharadwaj was selected as Board Member of the Indian School of Business (ISB), a Young Global Leader of the World Economic Forum (WEF), Board Member of Olympic Gold Quest (OGQ), Member of the Harvard Business School South Asia Advisory Board, Member of the Wharton Executive Education Board, Member of the Young Presidents’ Organization and previously chaired the FICCI Committee on Private Equity & Venture Capital.
Mr. Bharadwaj serves on the boards of Hexaware, Indegene Nxtra Data Centers, Piramal Pharma Limited, Sequent Scientific, Dailyhunt, CorroHealth and others. Previously, he served on the boards of Delhivery Logistics, Global Health, Metropolis Healthcare, Visionary RCM and others.
Mr. Bharadwaj holds an MBA with distinction from Harvard Business School, and graduated summa cum laude with a BS in economics from the Wharton School of the University of Pennsylvania.